2010 LorSand CME - Pain Medicine and Controlled Substances
Topic: Pain Medicine and Controlled Substances: Risk Management and Best Practices
Event Information
When
Saturday, Mar 06
07:00am (EST)
Where
Embassy Suites Tampa - USF
3705 Spectrum Boulevard
Tampa FL 33612
This event offers 8.0 CE credits to attendees
This event has a brochure you can download
Download Attendee registration packet-final.pdf - (61.77 KB)Additional Event Information
Guest Speaker(s): Lora L. Brown, MD, DABPM, DABIPP
"Pain Medicine and Controlled Substances: Risk Management and Best Practices"2010 Workshops
Prescription drug abuse (often referred to as the “Silent Epidemic”) has been identified as a major drug problem in the US. In Florida, 11 people daily died from prescription drug abuse in 2008. In addition, Florida has the highest rate of prescription drug abuse, and is the major distribution center of oxycodone for the remainder of the country.
Recent legislation (SB 462) was passed in Florida to help combat this epidemic. The Prescription Drug Validation Bill creates a prescription drug-monitoring database which, in other states has shown to reduce the problem of diversion. In addition, the law empowers the Florida Board of Medicine to regulate and control pain clinics throughout the state. The Board of Medicine has recently signaled that it plans to include mandatory CME’s for physicians in controlled substance prescribing for chronic pain.
“Pain Medicine and Controlled Substances: Risk Management and Best Practices” is a novel CME event, endorsed by the Florida Society of Interventional Pain Physicians that will offer healthcare providers the needed pain management medical education, legal and DEA updates, as well as compliance and risk management strategies that will keep them in the forefront of their specialty.
This day long event will provide 8 Continuing Education hours of intense and comprehensive review of pharmacology, neurobiology, risk management and legal ramifications related to the treatment of chronic pain. The diseases of Pain and Addiction will be discussed and all participants will be provided a practice risk management protocol for the assessment and management of patients who receive controlled substances for pain.
We look forward to your attending this critically important and timely Continuing Education activity “Pain Medicine and Controlled Substances: Risk Management and Best Practices”.
Sincerely yours,
Lora L. Brown, MD, DABPM, DABIPP
Board Certified Pain Medicine
Board Certified Anesthesiology
Board Certified in Interventional Pain